Scientists have developed a new tissue ‘scaffold’ technology that could one day enable the engineering of large organs
Research led by the Universities of Bristol and Liverpool has shown that it is possible to combine cells with a special scaffold to produce living tissue in the laboratory. It is hoped this can then be implanted into patients as a way of replacing diseased parts of the body.
Until now, the approach has generally been limited to growing small pieces of tissue, as larger dimensions reduce the oxygen supply to the cells in the centre.
A team of researchers, led by Dr Adam Perriman from the University of Bristol and Professor Anthony Hollander from the University of Liverpool, used cartilage tissue engineering as a model system for testing a new method of overcoming the oxygen limitation problem.
They synthesised a new class of artificial membrane binding proteins that can be attached to stems cells. By attaching an oxygen-carrying protein, myoglobin, to the stem cells before they are used to engineer cartilage, they ensure that each cell has its own oxygen reservoir that it can access when the oxygen in the scaffold drops to dangerously low levels.
Dr Perriman from Bristol’s School of Cellular and Molecular Medicine said: “From our preliminary experiments, we found that we could produce these artificial membrane binding proteins and paint the cells without affecting their biological function.
“However, we were surprised and delighted to discover that we could deliver the necessary quantity to the cells to supplement their oxygen requirements. It’s like supplying each cell with its own scuba tank, which it can use to breathe from when there is not enough oxygen in the local environment.”
The team’s findings, published today [17 June] in Nature Communications, could really expand the possibilities in tissue engineering, not only in cartilage, but also for other tissue such as cardiac muscle or bone.
Professor Hollander said: “We have already shown that stem cells can help create parts of the body that can be successfully transplanted into patients, but we have now found a way of making their success even better.
“Growing large organs remains a huge challenge but with this technology we have overcome one of the major hurdles.
“Creating larger pieces of cartilage gives us a possible way of repairing some of the worst damage to human joint tissue, such as the debilitating changes seen in hip or knee osteoarthritis or the severe injuries caused by major trauma, for example in road traffic accidents or war injuries.”
Their new methodology, describing the conversion of a normal protein into a membrane binding protein, is likely to pave the way for the development of a wide range of new biotechnologies.
Read more: Tissue ‘scaffold’ technology could help rebuild large organs
The Latest on: Tissue scaffold technology
[google_news title=”” keyword=”Tissue scaffold technology” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Tissue scaffold technology
- Global 3D Cell Culture Market Projected to Reach USD 3.21 Billion by 2030, Driven by Technological Advancementson March 28, 2024 at 7:44 am
Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Global 3D Cell Culture Market Size, Share & Trends Analysis Report by Technology (Scaffold Based, Scaffold Free, Bioreactors, Microfluidics, Bioprinting ...
- Bacterial Cellulose Scaffolds and Cellulose Nanowhiskers for Tissue Engineeringon March 21, 2024 at 5:00 pm
The most progress has been made in the field of vascular tissue engineering, using tubular scaffolds of BC as artificial vascular grafts. Efficacy has been demonstrated in vivo in animal models ...
- Tempo secures funding to advance tissue scaffold candidates into studieson March 20, 2024 at 5:09 am
Tempo Therapeutics has secured $12m in a Series A financing round to advance its synthetic tissue scaffold products into clinical trials. The financing round was led by Galaxy Sirius Partners and ...
- Tempo Therapeutics Secures Series A Financing to Advance Cutting-Edge Tissue Scaffold Products into Clinical Trialson March 19, 2024 at 3:32 pm
The funding will propel Tempo forward as it advances its revolutionary Microporous-Annealed-Particle (MAP) technology platform and takes its synthetic tissue scaffold candidates into clinical trials.
- A new approach to tissue engineering improves blood vessel formation in ratson March 15, 2024 at 7:39 am
"The perfusion in patterned blood vessels indicates that the new blood vessel network is functional, interconnected, and guided by the microarchitecture of granular hydrogel scaffolds. That represents ...
- Two-photon fabricationon February 19, 2024 at 7:16 am
An important factor in the production of tissue-engineering scaffolds is the ability to reproducibly manufacture 3D nanostructures; a direct application of 2PP technology. 2PP technology can also ...
via Bing News